—

Belite Bio Inc ADR (BLTE) — the peer cohort

As of 2026-11-17 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Belite Bio Inc ADR ranks 7 of 7 in its cohort on the Closelooknet composite (29/100) — the cohort is led by Halozyme Therapeutics Inc at 71/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
BLTE Belite Bio Inc ADR 29 57 7 10 warn 21.1%
HALO Halozyme Therapeutics Inc 71 67 94 49 info 28.4%
ONC BeOne Medicines AG 66 89 68 29 ok 2.7%
REGN Regeneron Pharmaceuticals Inc 65 90 73 47 neutral 4%
ARGX.BR Argen-X 64 75 75 26 ok 7.6%
RIGL Rigel Pharmaceuticals Inc 64 80 89 76 info 16.9%
UCB.BR UCB SA 64 77 71 42 info 4.8%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-11-17

Quick answers

Who are Belite Bio Inc ADR's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Halozyme Therapeutics Inc (HALO), BeOne Medicines AG (ONC), Regeneron Pharmaceuticals Inc (REGN), Argen-X (ARGX.BR), Rigel Pharmaceuticals Inc (RIGL), UCB SA (UCB.BR), as of 2026-11-17.

How does BLTE score against its peers?

Belite Bio Inc ADR's composite reads 29/100, ranking 7 of 7 in its cohort as of 2026-11-17; the cohort's highest composite is Halozyme Therapeutics Inc at 71/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.